Tempus AI (NASDAQ:TEM) Director Nadja West Sells 3,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director owned 31,981 shares of the company’s stock, valued at $2,206,689. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 1.2%

Tempus AI stock traded down $0.78 during midday trading on Tuesday, reaching $62.27. The stock had a trading volume of 6,218,304 shares, compared to its average volume of 6,083,589. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The company has a fifty day moving average of $54.93 and a 200 day moving average of $51.81. The firm has a market cap of $11.24 billion, a price-to-earnings ratio of -43.24 and a beta of 3.58. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. The company’s quarterly revenue was up 21.6% on a year-over-year basis. On average, analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after acquiring an additional 817,014 shares in the last quarter. ARK Investment Management LLC lifted its stake in shares of Tempus AI by 5.3% during the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after purchasing an additional 381,816 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Tempus AI by 6,379.2% during the 2nd quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock worth $404,189,000 after purchasing an additional 6,869,519 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. boosted its position in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Weiss Ratings lowered Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Lake Street Capital downgraded Tempus AI to a “hold” rating in a report on Monday, July 20th. Stifel Nicolaus lowered their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $67.23.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.